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Abstract
Purpose: The main aim of this study was to investigate the effects of Portulaca
oleracea extract on tumor formation in colon cancer stem cells and chemotherapy
sensitivity. In addition, this study analyzed the genetic changes within the Notch
signal transduction pathway associated with the effects of the extracts.
Methods: Serum-free cultures of colon cancer cells (HT-29) and HT-29 stem cells
were treated with the chemotherapeutic drug 5-FU to assess sensitivity. Injections of
the stem cells were also given to BALB/c mice to confirm tumor growth and
characteristics. In addition, the effect of different concentrations of P. oleracea
extract was tested on the growth of HT-29 and HT-29 stem cells, which was
determined by the MTT method. The effects of P. oleracea extract on the expression
of β-catenin, Notch1, and Notch2 in HT-29 cells were detected by RT-PCR and
Western blotting.
Results: The tumor volume of HT29 cells was two times larger than that of HT29
stem cells. Treatment with P. oleracea extracts inhibited the proliferation of both
HT-29 and HT-29 stem cells in doses from 0.07 - 2.25 μg/mL. Apoptosis of HT-29
and HT-29 stem cells, as assessed by flow cytometry, was enhanced by the addition of
P. oleracea extract. Finally, treatment with P. oleracea extracts significantly
down-regulated the expression of the Notch1 and β-catenin genes in both cell types.
Conclusion: This study shows that P. oleracea extract inhibits the growth of colon
cancer stem cells in a dose-dependent manner. Furthermore, it inhibits the expression
of the Notch1 and β-catenin genes. Taken together, this suggests that it may elicit its
effects through regulatory and target genes that mediate the Notch signal transduction
pathway.
xii

Key Words: Colon Cancer Stem Cells; Portulaca oleracea Extract; Notch Signal
Transduction Pathway
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1.0 Introduction and Study Background 1
1.1 Abstract
Cancer stem cells are cells which have been reported to have the ability to
self-differentiate and self-renew. In colon cancer, the cells have been shown to play a
significant role in tumorigenesis, abnormal differentiation, recurrence, and metastasis
of colon cancer. Additionally, research has shown that the cancer stem cells are
insensitive to chemotherapy and immunotherapy, hence the need for an alternative
therapy. The use of herbal medicines is seen as a viable alternative with reports
indicating that P. oleracea extracts have the ability inhibit a number of different
cancer cell types. However, the effectiveness of P. oleracea extracts in inhibiting
colon cancer stem cells has not been investigated. Also, although it is known that
dysregulations of the Notch signal transduction pathway play a significant role in the
development of colon cancer stem cells, no study has been conducted to investigate
the effects of P. oleracea extracts on Notch signal transduction pathway. Therefore,
the purpose of this study was to determine if P. oleracea extracts can inhibit colon
cancer stem cells, and if the effects observed are mediated by the Notch signal
transduction pathway.

1

The material contained in this chapter was already submitted to Tumor Biology.

1

1.2 Introduction
Colon cancer is a significant public health problem worldwide ranked as the
fourth leading cause of cancer-related mortalities worldwide (S. Liu et al., 2015). The
development, recurrence, and metastasis of colon cancer cells are mediated by colon
cancer stem cells, a small proportion of tumor cells that can self-renew, infinitely
proliferate, and have the potential for multi-directional differentiation. The stem cells
must be inhibited in the initiating cells associated with carcinogenesis to maintain the
growth of the tumor (Kucia et al., 2005). It was once believed that tumor stem cells
only existed in hematological and lymphocytic malignancies; however, it is now
known that tumor stem cells heavily influence all solid tumors (Patrawala et al., 2005;
Setoguchi et al., 2004).
Some cells present in human colon crypts can self-renew and differentiate.
Mediated by a series of genes that maintain a dynamic balance in the colon, these
stem cells play an important role in the regeneration and restoration of the organ
(Dhawan, Ahmad, Srivastava, & Singh, 2011). External forces, such as mutations, can
have long-term effects when they impact colon stem cells. During a prolonged period
of time, oncogene mutations can accumulate thereby promoting the transformation of
stem cells and the asymmetric division of stem cells and ultimately leading to the
2

production of colon cancer stem cells (Dhawan et al., 2011). Colon cancer stem cells
have the same self-differentiation and self-renewal characteristics of normal colon
stem cells; however, cancer stem cells play a role in tumorigenesis and abnormal
differentiation (L Ricci-Vitiani, Pagliuca, Palio, Zeuner, & De Maria, 2008). In
clinical practice, stem cells do not invade the tumor but rather are present during the
earliest stages of colon cancer. Additionally, cancer stem cells are present only at the
primary tumor site and do not appear to be involved in distant metastases. However,
recent studies have indicated that colon cancer stem cells are important to the
recurrence and metastasis of colon cancer (Dhawan et al., 2011; L Ricci-Vitiani et al.,
2008).
Currently, many molecular markers can be used to identify and isolate colon
cancer stem cells. The most commonly used molecular markers include CD133 and
CD44, as well as CD24, epithelial-specific antigen (ESA), CD166, CD29, and
leucine-rich repeat containing G protein-coupled receptor (Lgr) (Dalerba, Dylla, et al.,
2007; Kemper et al., 2012; O’Brien, Pollett, Gallinger, & Dick, 2007; Lucia
Ricci-Vitiani et al., 2007; Todaro et al., 2007; Vermeulen et al., 2008). Most colon
cancer stem cells have been reported to be insensitive to chemotherapy and
immunotherapy, and these cells are thought to be involved in the development of
resistance to chemotherapy (Dhawan et al., 2011). Taken together with their
3

important roles in many cancer processes, these cells may be an important target for
the prevention and treatment of colon cancer (Dhawan et al., 2011).
At present, there are no effective methods for the suppression of colon cancer
stem cells. Previous studies have found that the foods used in traditional Chinese
medicine can prevent and treat colon cancer; for example, extract from the edible
vegetable P. oleracea has been shown to inhibit a number of different cancer cell
types (H.-Y. Jin, Zhang, Wang, Xu, & Ding, 2012). However, at present no study has
yet determined the effect of P. oleracea extract on colon cancer stem cells.
Additionally, the Notch signal transduction pathway has been shown to be important
for the development of colon cancer stem cells (H.-Y. Jin et al., 2012; Qiao & Wong,
2009). Therefore, the purpose of this study was to determine if P. oleracea can inhibit
colon cancer stem cells, and if the effects observed were mediated by the Notch
signal transduction pathway.
1.3 Study Background
1.3.1

Colon Cancer: Epidemiology

Colon cancer, also known as colorectal cancer, accounts for more than 9% of all
the cases of cancers in the world (Haggar & Boushey, 2009) and the third most
common type of cancer worldwide (Fitzmaurice et al., 2015). Epidemiological data
have also shown that colon cancer is the fourth leading cause of cancer-related
4

mortalities worldwide (S. Liu et al., 2015). The cancer is common in both men and
women with reports indicating that the cancer accounts for 9.4% of all cancer
incidences in men and 10.1% in women (Haggar & Boushey, 2009). Therefore, colon
cancer is a significant public health problem worldwide requiring appropriate and
effective therapy.
1.3.2

Colon Cancer: Causes and Risk Factors

There are several factors which have been shown to be risk factors and/or causes
of colon cancer. The factors are grouped into environmental, other health conditions
and genetic factors as well as interactions between the genetic and environmental
factors. Environmentally, obesity (Bardou, Barkun, & Martel, 2013), sedentary
lifestyle (Durko & Malecka-Panas, 2014; Shen et al., 2014) and unhealthy dietary
(Béliveau & Gingras, 2007; Myles, 2014) habits have been shown to increase the risk
of colon cancer in both women and men.
According to Bardou, Barkun, and Martel (2013), obesity leads to metabolic
syndromes, insulin resistance and dysregulation of adipocytokines levels which
results in increased risk of colon cancer. Through these mechanisms, obesity is also
associated with poor cancer outcomes including recurrence ad metastasis of the
cancers as well as increased mortalities (Bardou et al., 2013). Indeed, it has also been
reported that hyperinsulinemia, due to obesity-associated type 2 diabetes mellitus,
5

plays a significant role in the pathogenesis and spread of colon cancer (Frezza, 2006).
A systematic literature review of studies by Ma et al. (2013) also found that obesity is
associated with up to 60% greater risk of colon cancer when compared to individuals
with normal body mass index. Therefore, the available research evidence indicates
that obesity does not only increase the risk of developing colon cancer by up to 60%,
but is also associated with poor clinical outcomes of the cancer.
Sedentary lifestyle is another environmental factor which has been associated
with the risk of colon cancer. According to Shen et al. (2014), a sedentary lifestyle
characterized by low levels of physical activity is associated with obesity and poor
weight management which in turn increases the risk of colon cancer and results in
poor clinical outcomes among patients with the cancer. Boyle, Fritschi, Heyworth and
Bull (2011) also found that people who spent 10 or more years in sedentary work had
twice the risk of colon cancer when compared to the people who did not spend any
time in sedentary work. The Boyle et al. (2011) study also found that the association
between sedentary lifestyle and colon cancer was independent of recreational
physical activity. The findings demonstrate the significant role played by sedentary
lifestyle in increasing the risk of developing colon cancer. The association can occur
via obesity, where the sedentary lifestyle increases the body mass index of a person,
or directly where the sedentary lifestyle results in colon cancer independent of body
6

weight and physical activity.
Like sedentary lifestyle, unhealthy eating habits such as consumption of highcalorie food and food rich in fats can result in obesity which in turn increases the risk
of developing colon cancer and/or complicates the clinical outcomes of the cancer
(Myles, 2014). Research has also shown that high-fat contents in food disrupt the
composition of the gut normal flora which in turn increase the risk of colon cancer
(Zackular et al., 2013). Indeed, the Zackular et al. (2013) study established that
patients with colon cancer have altered gut flora when compared to healthy patients.
The study also found that the manipulation of gut flora in mice with antibiotics
increased the number and size of the gut tumours. The findings suggest that
disruption of the gut microbiota increases the risk and pathogenesis of colon cancer.
Therefore, consumption of high-fat content foods which alters the gut microbiota
increases the risk of colon cancer and may be associated with the pathogenesis,
invasion, and metastasis of the cancer.
In addition to these environmental factors, other factors such as alcohol
consumption and tobacco smoking have also been reported to be significantly
associated with colon cancer (Cho et al., 2015). It is known that consumption of
alcohol and smoking cigarette are major risk factors for gastrointestinal cancers
including colon cancer (Cho et al., 2015). Alcohol is a carcinogen (group 1
7

carcinogen) which has been shown to be a significant contributor to the risk of colon
cancer (Tsong et al., 2007). Indeed, a study cited by Tsong et al. (2007) found that
there is 30% higher risk of colon cancer in people who consume two alcoholic drinks
per day compared to non-drinkers. Similarly, cigarette is a carcinogen which has been
associated with the risk of colon cancer at a relative risk of 1.19 at 95% confidence
interval (Limsui et al., 2010). Botteri et al. (2008) also found that ever-smokers are
18% more likely to develop colon cancer compared to non-smokers. Research has
also shown that the metabolites of cigarette such as cotinine, O-cresol sulfate, and
hydroxycotinine are the carcinogens that induce colon cancer in cigarette smokers
(Cross et al., 2014).
In addition, certain health conditions such as gastrointestinal inflammation and
high blood levels of insulin have also been associated with colon cancer. According to
Terzić, Grivennikov, Karin and Karin (2010), the association between gastrointestinal
inflammations such as inflammatory bowel disease and colon cancer is
well-established. During inflammation, activated inflammatory cells produce reactive
oxygen species (ROS) and reactive nitrogenous metabolites which cause DNA
damage and mutations resulting in uncontrolled cell proliferation and cancer (Terzić
et al., 2010). Therefore, gastrointestinal inflammation results in the production of
ROS and reactive nitrogenous intermediates which induce DNA mutations in the
8

colon leading to colon cancer. High levels of insulin in blood has also been shown to
increase the risk of colon cancer. According to Johnson and Gale (2010), insulin is a
mitogenic hormone and overexpresses their receptors on the surface of cancer cells if
present in high levels in the blood. Therefore, high level of insulin in blood acts as
tumour growth factors which promote the development and spread of cancer cells.
Increased levels of insulin in the blood, like the case in type 2 diabetes mellitus due to
insulin resistance can, therefore, promote the development and spread of colon cancer
cells.
Genetically, research has shown that up to 10% of all the cases of colon cancer
are hereditary conditions (Jackson-Thompson, Ahmed, German, Lai, & Friedman,
2006). The mist common hereditary colon cancers are hereditary nonpolyposis colon
cancer and familial adenomatous polyposis (Haggar & Boushey, 2009). Hereditary
nonpolyposis colon cancer is caused by is due to mutations in genes that regulate
DNA repair such as the MLH1 and MSH2 genes. Mutations in these genes (MLH1
and MSH2 genes) results in hereditary nonpolyposis colon cancer, which accounts for
approximately 2% to 6% of all the forms of colon cancer (Haggar & Boushey, 2009).
Familial adenomatous polyposis is caused by mutations in the APC gene (a tumour
suppressor gene) which occur in an autosomal dominant manner (Haggar & Boushey,
2009).
9

Interactions between genetic and environmental factors also contribute to the risk
of developing colon cancer. For instance, increased physical activity has been shown
to interact with certain genes to influence the clinical outcome of the cancer (Marley
& Nan, 2016). Indeed, it has been shown that the level of physical activity with colon
cancer survival in patients diagnosed to be prostaglandin-endoperoxide synthase
2-positive (PTGS2-positive) (Yamauchi et al., 2013). Similarly, Meyerhardt et al.
(2009) found that physically active colon cancer patients with P27 expression had a
68% lower mortality rates from the cancer compared to colon cancer patients who
were physically inactive. In addition, further research has shown that the interaction
between environmental factors such as alcohol consumption, obesity, intake of
vitamin D and intake of polyunsaturated fatty acids have also been shown to
influence the risk of colon cancer (Marley & Nan, 2016; Morikawa et al., 2013).
1.3.3

Colon Cancer Stem Cells and Colon Cancer

1.3.3.1 Differences between Colon Cancer Stem Cells and Colon Cancer Cells
In addition to environmental and genetic factors, colon cancer stem cells also
play a significant role in the development, recurrence and metastasis of colon cancer
(Dhawan et al., 2011; L Ricci-Vitiani et al., 2008), hence the need to identify the stem
cells for diagnosis and treatment. Cancer stem cells are a small sub-population of
tumour cells with the ability to efficiently propagate cancer development and
10

pathogenesis (Puglisi, Tesori, Lattanzi, Gasbarrini, & Gasbarrini, 2013). Therefore,
cancer stem cells can be defined as a small proportion of tumor cells, making 0.1to
10% of tumour cells (Deonarain, Kousparou, & Epenetos, 2009), that can self-renew,
infinitely proliferate, and have the potential for multi-directional differentiation.
Cancer cells are abnormal cells capable of differentiating and proliferating
indefinitely and can invade surrounding tissues and metastasize to distant organs
(Sitas et al., 2006). The cancer cells can either be benign or malignant. Benign cancer
cells are tumours that remain confined to the original site of location without
invading the surrounding tissues or metastasizing to distant organs. Malignant
tumours are cancer cells with abnormal and unregulated proliferation and
differentiation with the ability to invade surrounding tissues and metastasize to distant
organs (Sitas et al., 2006). On the other hand, cancer stem cells are cells within
benign or malignant tumours with the same characteristics as normal stem cells (can
give rise to new cells) (Magee, Piskounova, & Morrison, 2012).
Since cancer stem cells form a small sub-population of tumour cells, their
identification can be challenging. However, comparison of other cancer stem cells
and cancer cells have revealed some significant differences which can be used to
identify and isolate colon cancer stem cells. For instance, it has been reported that
cancer cells and cancer stem cells can be distinguished based on their sensitivity to
11

chemotherapeutic agents where cancer stem cells have been found to be more
insensitive to the agents than cancer cells (Vinogradov & Wei, 2012). The expression
of CD133 and CD44 has also been utilised as a basis of differentiating cancer cells
from cancer stem cells. For instance, it has been shown that cancer stem cells have
higher expression of CD133 and CD44 compared to cancer cells (Guo, 2012; Nagata
et al., 2011). Other reports have also established that cancer cells take up more
Hoechst33342 stain and have a higher growth rate compared to cancer cells (Gao,
Geng, Kvalheim, Gaudernack, & Suo, 2009; Toloudi et al., 2014).
1.3.3.2 Role of Colon Cancer Stem Cells in Cancer Development, Recurrence and
Metastasis
There is research evidence to show that colon cancer stem cells are associated
with development (Abdul Khalek, Gallicano, & Mishra, 2010), recurrence
(Ramasamy, Ayob, Myint, Thiagarajah, & Amini, 2015) and metastasis (Basu, Haase,
& Ben-Ze’ev, 2016) of colon cancers. When compared to normal stem cells, cancer
stem cells has no restricted or regulated rate of proliferation and have a slow rate of
cycling which plays a significant role in tumour recurrence and initiating resistance to
chemotherapy and radiotherapy (Moore & Lyle, 2011; Pannuti et al., 2010). In
addition, cancer stem cells have the ability to initiate new tumours hence plays a
significant role in metastatic colorizations (Hanahan & Weinberg, 2011).
12

1.3.3.3 Properties of Colon Cancer Stem Cells
The main properties of colon cancer stem cells include self-renewal potential,
ability to differentiate into diverse cell populations and ability to balance and
modulate the processes of self-renewal and differentiation (Garza-Treviño,
Said-Fernández, & Martínez-Rodríguez, 2015). Self-renewal refers to the ability of
the colon cancer stem cells synthesize new cells with the same ability to proliferate,
expand and differentiate as the parental cells thereby maintaining a pool of the stem
cell (Garza-Treviño et al., 2015). The mechanisms utilised for the self-renewal of the
colon cancer stem cells, such as the Wnt/β-catenin and Notch pathways, makes use of
proto-oncogenes. In addition, the self-renewal pathway of colon cancer stem cells is
regulated by the sonic hedgehog (Hh) signaling pathway, a pathway commonly
reported in multiple myeloma (Varnat et al., 2009). Research has shown that the
self-renewal of colon cancer stem cells is promoted by the Wnt pathway and the
prevention of the β-catenin-dependent transcription (Ong, Vega, & Houchen, 2014).
Additionally, the Notch receptors pathway have also been reported to promote
the self-renewal of colon cancer stem cells (Ong et al., 2014). In the Notch pathway,
the DLL4 genes stimulate the Notch receptors on adjacent cells and in combination
with the effects of β-catenin promotes the self-renewal of the cancer stem cells by
directing an immature transcription profile (Garza-Treviño et al., 2015). However, the
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self-renewal pathways are inhibited by BMP4 genes which bind BMP receptors
leading to interference with the Wnt pathway and thus promote cell differentiation.
The process of differentiation has also been reported to be inhibited by hepatocyte
growth factor (HGF) leading to the maintenance of the cells in a stem-cell state (Ong
et al., 2014).
Cancer stem cells also have the ability into differentiate to diverse cell
populations (Garza-Treviño et al., 2015). That is, the stem cells have the ability to
differentiate into a heterogeneous progeny of cells that can undergo progressive
diversification and specialization following self-renewal. The cells of this
differentiation are specialized to carry out certain unique physiological functions
(Dalerba, Cho, & Clarke, 2007). However, histopathological studies of colon cancers
have indicated that the cells are relatively undifferentiated containing higher
proportions of colon cancer stem cells than more differentiated cancer cells (Ashley,
Yeung, & Bodmer, 2013; Merlos-Suárez et al., 2011). The undifferentiated colon
cancer cells have worse clinical prognosis compared to differentiated cancer cells
(Merlos-Suárez et al., 2011).
Homeostatic control where the cells have the ability to balance and modulate the
processes of self-renewal and differentiation is also a key property of cancer stem
cells (Garza-Treviño et al., 2015). Through research, it has been established that
14

differentiated intestinal epithelial cells reside in the intestinal crypts as repeats of
stem cells containing leucine and B lymphoma Mo-MLV insertion region 1 homolog
(Bmi-1) or G protein-coupled receptor 5 (Lgr5) (Tian et al., 2011). The Bmi-1 AND
Lgr5 are used to maintain the capacity of tissues to regenerate (Tian et al., 2011). The
intestinal cells that express Lgr5 undergo active proliferation and very sensitive to
stimulatory effects of Wnt and Dkk1-mediated Wnt inhibition (Tian et al., 2011). On
the other hand, intestinal cells that express Bmi-1 are less sensitive to environmental
stressors and are, therefore, not affected by the Wnt modulation. The
Bmi-1-expressing intestinal cells are normally quiescent, only giving rise to cell
progeny under certain conditions (Yan et al., 2012). The Wnt proteins and the Notch
pathway has been reported to play a significant role in maintaining cancer stem cells
hemostasis by providing signals required for the maintenance of the phenotype of
colon cancer stem cells in the tumour mass (Garza-Treviño et al., 2015).

1.3.3.4 Markers of Colon Cancer Stem Cells
Colon surface antigens on the surface of the stem cells have been identified as the
markers for colon cancer stem cells. According to Deonarain et al. (2009), these
antigens are not identified based on their overexpression on typical tumour cells, but
on their presence in a population of cells with stem cell-like properties. However, the
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identification of the cancer stem cell antigen has been challenging due to their
variable expression on cancer stem cells and frequent co-expression in normal stem
cells (Deonarain et al., 2009). Currently, many molecular markers have been
discovered for the identification and isolation of colon cancer stem cells.
The most commonly used molecular markers include CD133 and CD44, as well
as CD24, epithelial-specific antigen (ESA), CD166, CD29, and Lgr (Dalerba, Dylla,
et al., 2007; Kemper et al., 2012; O’Brien et al., 2007; Lucia Ricci-Vitiani et al., 2007;
Todaro et al., 2007; Vermeulen et al., 2008). Most colon cancer stem cells have been
reported to be insensitive to chemotherapy and immunotherapy, and these cells are
thought to be involved in the development of resistance to chemotherapy (Dhawan et
al., 2011). Taken together with their important roles in many cancer processes, these
cells may be an important target for the prevention and treatment of colon cancer
(Dhawan et al., 2011).
1.3.4

Colon Carcinogenesis

The transformation of normal cells to cancer cells requires six hallmarks;
self-sufficiency in signals required for growth, the potential for unlimited replication,
insensitivity to snit-growth signals, ability to evade apoptosis, tissue invasion and
sustained angiogenesis (Garza-Treviño et al., 2015). Initially, there must be genetic
defects within the cell that result in DNA instability and then inactivation of tumour
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suppressor genes. This results in uncontrolled cell division, differentiation, and
self-renewal leading to cancer development (Garza-Treviño et al., 2015).
In colon cancer, the transformation of normal intestinal cells to colon cancer cells
begins with an increase in the intracellular β-catenin in normal colon epithelial tissue.
This results in prolonged activation of the Wnt pathway, stabilization of β-catenin,
and activation of the C-terminal binding protein 1 (CtBP1) (Garza-Treviño et al.,
2015). Additionally, there is inactivation of the APC gene which initiates adenoma
while the nuclear localization and activation of β-catenin promote the activation of
the formed adenoma to carcinoma (Phelps et al., 2009). The progression of colon
tumours is driven by mutations in phosphatidylinositol 3-kinase (PIK3CA) and
transforming growth factor-beta receptor (TGFBR) genes (Armaghany, Wilson, Chu,
& Mills, 2012). In addition to these mechanisms, research has also established that
normal stem cells, instead of progenitor and differentiated cells, are also involved in
the initiation of colon cancers of cellular origin (Armaghany et al., 2012).
1.3.5

Colon Cancer Stem Cells in Colon Carcinogenesis

Cancer stem cells are transformed to more malignant phenotypes during the
process of primary cancer progression via three main pathways; microsatellite
instability (defects in DNA mismatch repair), chromosomal instability, and CpG
island methylator phenotype pathways (Pino & Chung, 2010). These carcinogenic
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pathways cooperate leading to the activation of different downstream signaling
effectors such as mitogen-activated protein kinases (MAPKs), PI3K/Akt/molecular
target of rapamycin (mTOR) and nuclear factor-kappaB (NF-kB) conferring
high-level self-renewal ability to the cells (Birnie et al., 2008; Chiba et al., 2008; S.
Ma, Lee, Zheng, Chan, & Guan, 2008; Mimeault, 2012; Shiras et al., 2007;
Venugopal et al., 2012; Wang et al., 2012). In addition to transforming themselves to
more malignant phenotypes, colon cancer stem cells also initiate the development,
recurrence, and metastasis of colon cancers (Dhawan et al., 2011; L Ricci-Vitiani et
al., 2008).
1.3.6

Chemotherapy and Chemoresistance

Colon cancer is primarily managed with chemotherapy regiments of “5
fluorouracil (5FU), oxaliplatin and/or leucovorin or 5-FU, leucovorin and irinotecan
(FOLFIRI)” (Garza-Treviño et al., 2015, p.2). The drugs display anti-cancer
properties by inducing oxidative damage of the cancer cells. However, the
chemotherapy regimen has been reported to be ineffective leading to treatment
failures in 90% of metastatic colon cancer and this has been attributed to
chemoresistance (Zhao, Butler, & Tan, 2013). The oxidative damage of the cancer
cells increases the glycolysis of the cells resulting in high levels of the antioxidant
NADPH, which can be associated with chemoresistance (Wu, Calcagno, & Ambudkar,
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2008).
Colon cancer stems also displays chemoresistance by expressing HIF-1α which
decreases the pro-apoptotic signaling. The expression of HIF-1α induces the
expression of decoy receptors like DcR2 which competes for the pro-apoptotic
signaling factors such as the tumor necrosis factor-related apoptosis inducing ligand.
This reduces the signaling through the apoptosis-inducing receptors and, therefore,
attenuates apoptosis thereby allowing cells to tolerate high levels of chemotherapeutic
agents (Chen et al., 2009; Flamant, Notte, Ninane, Raes, & Michiels, 2010; Sullivan
& Graham, 2009; Wen et al., 2010). Indeed, there is research evidence to show that
most colon cancer stem cells are insensitive to chemotherapy and immunotherapy,
leading to the development of resistance to chemotherapy (Dhawan et al., 2011).
1.3.7

Treatment Implications of Colon Cancer Stem Cells

Colon cancer stem cells play a significant role in the development, recurrence,
and metastasis of colon cancer and can, therefore, be an important target for the
prevention and treatment of colon cancer (Dhawan et al., 2011). The cancer stem cells
are insensitive to chemotherapy hence the need for alternative therapy. Research has
shown that immunotherapy with antibodies can be utilised as an alternative therapy.
For instance, studies have shown that colon cancer stem cells that are insensitive to
5FU can be made sensitive by the use of interleukin-4 blocking antibody (Todaro et
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al., 2007; Todaro, Perez Alea, Scopelliti, Medema, & Stassi, 2008). Similarly, it has
been demonstrated that the use of anti- epiregulin, epidermal growth factor family
(anti-EREG) antibodies is an effective immunotherapy against colon cancer
metastasis (Kobayashi et al., 2012). Therefore, there is research evidence to
demonstrate the effectiveness of immunotherapy against colon cancer stem cells.
However, immunotherapy is an expensive alternative to chemotherapy due to the high
cost of producing, storing and transporting the antibodies (Lynch & Murphy, 2016).
Alternatively, nanotechnology can also be utilised to suppress colon cancer stem
cells which are resistant to chemotherapy. For instance, siRNA-mediated knockdown
of the drug efflux protein MDR1 (the protein is overexpressed in colon cancer stem
cells) has

been

described

as

a nanotechnology method

of overcoming

chemoresistance by the colon cancer stem cells (Liu et al., 2009). However,
nanotechnology is also an expensive therapy which cannot be afforded by most colon
cancer patients (Kim, Buddolla, & Lee, 2016). Therefore, a more affordable and
effective alternative is necessary to overcome the chemoresistance of colon cancer
stem cells in the treatment of colon cancers.
1.3.8

Portulaca oleracea Extracts for the Inhibition of Colon Cancer Stem Cells

As discussed earlier, the chemoresistance of colon cancer stem cells, despite their
significant role in the development, recurrence, and metastasis of colon cancers, can
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be overcome by immunotherapy (Kobayashi et al., 2012) and nanotechnology (Liu
et al., 2009). However, these therapies are expensive and may not be affordable to
many colon cancer patients(Kim et al., 2016; Lynch & Murphy, 2016). Therefore, a
more affordable but effective alternative is necessary to overcome the
chemoresistance. The use of medicinal plants has been utilised as an affordable
alternative for cancer therapy and can also be utilised to overcome the
chemoresistance of colon cancer stem cells. For instance, a study by Min, Lim, Kim,
Kim, and Kim (2015) found that the leaves of Sasa quelpaertensis can inhibit colon
cancer stem cells and influence gene expression related to stem cell development. In
another study, Kumar, Kumar, Raina, Agarwal and Agarwal (2014) found that grape
seed extract can inhibit the effect of colon cancer stem cells. P. oleracea extracts, a
traditional Chinese medicine can prevent and treat colon cancer. Extracts of the plant
have been to inhibit a number of different cancer cell types (H.-Y. Jin et al., 2012).
However, at present no study has yet determined the effect of P. oleracea extract on
colon cancer stem cells. Therefore, the purpose of this study was to determine if P.
oleracea can inhibit colon cancer stem cells, and if the effects observed were
mediated by the Notch signal transduction pathway.
1.4 Aims of the Study
Colon cancer stem cells have the ability to self-differentiate and self-renew and
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play a significant role in tumorigenesis and abnormal differentiation (L Ricci-Vitiani
et al., 2008). Although the stem cells do not invade tumors, they are present during
the early stages of colon cancer development and have been shown to play a
significant role in the recurrence and metastasis of colon cancer (Dhawan et al., 2011;
L Ricci-Vitiani et al., 2008). In addition, research has shown that most cancer stem
cells are insensitive to chemotherapy and immunotherapy and contributes to the
development of resistance to chemotherapy (Dhawan et al., 2011). Despite the
significant role played by the stem cells in the pathogenesis of cancers and resistance
to chemotherapy, there are no effective methods for the suppression of colon cancer
stem cells currently.
However, previous studies have found that the foods used in traditional Chinese
medicine can prevent and treat colon cancer; for example, extract from the edible
vegetable P. oleracea has been shown to inhibit a number of different cancer cell
types (H.-Y. Jin et al., 2012). The effectiveness of the P. oleracea vegetable in
inhibiting colon cancer stem cells has, however, not been investigated. In addition,
research has shown that Notch signal transduction pathway plays a significant role in
the development of colon cancer stem cells (H.-Y. Jin et al., 2012; Qiao & Wong,
2009). Therefore, dysregulation of the Notch signal transduction pathway by this
vegetable can it the development of colon cancer stem cells. As a result, the main
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purpose of this study was to determine if P. oleracea extracts can inhibit colon cancer
stem cells, and if the effects observed were mediated by the Notch signal transduction
pathway. This was accomplished by meeting the following general and four specific
objectives.
1.4.1

General Objective

To investigate the role and mechanism of P. oleracea extracts in inhibiting the
proliferation of colon cancer stem cells.
1.2.2
•

Specific Objectives
To investigate the differences between colon cancer cells (HT29 cells) and
colon cancer stem cells (HT29 stem cells)

•

To determine if P. oleracea extracts can inhibit colon cancer stem cells

•

To investigate the dysregulations of the Notch signal transduction pathway in
P. oleracea extracts-mediated inhibition of colon cancer stem cells
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2.0 Chapter 1: Differences between HT29 Cancer Cells and HT29 Stem Cells
2.1 Abstract
Identification of the unique features of cancer stem cells that can be used to
differentiate them from cancer cells is significant to the management of cancers due
to their association with cancer development, recurrence, and metastasis. This study
used HT29 colon cancer cells and HT29 colon cancer stem cells to compare the
characteristics of the two cell lines. The cells were cultured in RPMI-1640 medium
with 10% fetal bovine serum (FBS) and then flow cytometric analysis of cd133 and
cd44, chemotherapy drug sensitivity assay, Hoechst 33342 staining, proliferation
assessment and in vivo tumorigenesis assay carried out. The results showed that the
HT29 colon cancer stem cells have a significantly higher Hoechst33342 staining,
significantly increased expression of CD133 and CD44 markers, significantly faster
growth and have a lower sensitivity to chemotherapeutic drug 5-FUdrug compared to
the HT29 colon cancer cells. These characteristics can be used in clinical practice to
differentiate colon cancer stem cells from colon cancer cells for diagnostic purposes.
All institutional and national guidelines from Chinese Association for Laboratory
Animal Science for care and use of laboratory animals were followed. 2

2

The material contained in this chapter was already submitted to Tumor Biology.
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2.2 Introduction
There is research evidence to show that colon cancer stem cells are associated
with the development (Abdul Khalek et al., 2010), recurrence (Ramasamy et al., 2015)
and metastasis (Basu et al., 2016) of colon cancers. These cells form a small
sub-population of tumour cells with the ability to efficiently propagate cancer
development and pathogenesis (Puglisi et al., 2013). Therefore, cancer stem cells can
be defined as a small proportion of tumor cells, making 0.1to 10% of tumour cells
(Deonarain et al., 2009), that can self-renew, infinitely proliferate, and have the
potential for multi-directional differentiation.
On the other hand, cancer cells are abnormal cells capable of differentiating and
proliferating indefinitely and can invade surrounding tissues and metastasize to
distant organs (Sitas et al., 2006). The cancer cells can either be benign or malignant.
Benign cancer cells are tumours that remain confined to the original site of location
without invading the surrounding tissues or metastasizing to distant organs.
Malignant tumours are cancer cells with abnormal and unregulated proliferation and
differentiation with the ability to invade surrounding tissues and metastasize to distant
organs (Sitas et al., 2006). On the other hand, cancer stem cells are cells within
benign or malignant tumours with the same characteristics as normal stem cells (can
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give rise to new cells) (Magee et al., 2012).
Since cancer stem cells form a small sub-population of tumour cells, their
identification can be challenging. However, comparison of other cancer stem cells
and cancer cells have revealed some significant differences which can be used to
identify and isolate colon cancer stem cells. For instance, it has been reported that
cancer cells and cancer stem cells can be distinguished based on their sensitivity to
chemotherapeutic agents where cancer stem cells have been found to be more
insensitive to the agents than cancer cells (Vinogradov & Wei, 2012). The expression
of CD133 and CD44 has also been utilised as a basis for differentiating cancer cells
from cancer stem cells. For instance, it has been shown that cancer stem cells have
higher expression of CD133 and CD44 compared to cancer cells (Guo, 2012; Nagata
et al., 2011). Other reports have also established that cancer cells take up more
Hoechst33342 stain and have a higher growth rate compared to cancer cells (Gao et
al., 2009; Toloudi et al., 2014).
Currently, many molecular markers can be used to identify and isolate colon
cancer stem cells. The most commonly used molecular markers include CD133 and
CD44, as well as CD24, epithelial-specific antigen (ESA), CD166, CD29, and
leucine-rich repeat containing G protein-coupled receptor (Lgr) (Dalerba, Dylla, et al.,
2007; Kemper et al., 2012; O’Brien et al., 2007; Lucia Ricci-Vitiani et al., 2007;
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Todaro et al., 2007; Vermeulen et al., 2008). Most colon cancer stem cells have been
reported to be insensitive to chemotherapy and immunotherapy, and these cells are
thought to be involved in the development of resistance to chemotherapy r (Dhawan
et al., 2011). Taken together with their important roles in many cancer processes,
these cells may be an important target for the prevention and treatment of colon
cancer (Dhawan et al., 2011).
Indeed, the identification of cancer stem cells has been shown to be critical in the
management of cancers because inhibiting such stem cells will reduce the risk of
cancer development and recurrence (Huang, Cheng, Guryanova, Wu, & Bao, 2010).
Therefore, it is important to understand the differences between colon cancer cells
and colon cancer stem cells for the identification of the later. An example of cancer
cell lines is the HT29 cancer cells which are derived from human colon carcinoma
cells (Schreier et al., 2014). The HT29 stem cells are examples of cancer stem cells
derived from human colon carcinoma cells (Yeung, Gandhi, Wilding, Muschel, &
Bodmer, 2010). In this study, the HT29 cancer cells and HT29 stem cells were used to
investigate the differences in the characteristics of cancer cells and cancer stem cells.
2.3 Materials and Methods
2.3.1

Cell Culture

The colon cancer cells and colon cancer stem cells were cultured and separated
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as previously described (Todaro et al., 2007; Vermeulen et al., 2008). Briefly, the cells
of the HT29 human colon cancer cell line were cultured in RPMI-1640 medium with
10% fetal bovine serum (FBS) until they reached 90% confluence, at which point the
cells were collected. Next, the cells were centrifuged and the supernatant was
removed. The cells were re-suspended in serum-free DMEM/F12 medium
(containing 20 ng/mL epidermal growth factor, 10 ng/mL basic fibroblast growth
factor, 5 µg/mL insulin, 0.4% bovine serum albumin, and 2% B27), counted, and then
cultured in 6-pore suspension culture plates at a concentration of 1×104 cells/mL at
37°C and 5% CO2. After culturing for 3-7 days, the growth of the glomus cells could
be visualized. After 30 minutes at 37°C, the cells precipitated, and the supernatant
was removed (containing a small amount of individual cells and cell debris).
Serum-free DMEM/F12 was added for an expanded culture. After centrifuging the
glomus cells, digestion and passage, as well as cultivation, was performed for several
generations to purify the cells. Finally, the cells were collected for drug sensitivity
testing, proliferation assays, flow cytometry, and Hoechst 33342 staining, as
indicated.
2.3.2

Flow Cytometric Analysis of CD133 and CD44

HT-29 cells and HT-29 stem cells were first scattered and digested with
EDTA-containing trypsin, before quickly diluting and mixing with DMEM/F12
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medium. After centrifuging at 1500 rpm for 5 min, the supernatants were removed
and the cells were washed twice with PBS. Cells were re-suspended in 300 µL of
PBS and a homogenous mixture was obtained before each cell suspension was
divided into three separate suspensions, each consisting of 100 µL, which received
different treatments. The first was used as a blank/control. The second was treated
with 10 µL of anti-CD44-APC in the dark for 15 minutes at 4°C. The third was
treated with 10 µL of Fcr Block for 15 minutes at 4°C, and then received 10 µL of
anti-CD133-APC for 20 minutes at 4°C. The third was treated with 10 µL of Fcr
Block for 15 minutes at 4°C, and then received 10 µL of both anti-CD133-APC and
anti-CD44-APC for 20 minutes at 4°C (all procedures were carried out in the dark),
before washing with PBS. All cells were re-suspended in 400 µL of PBS and then
used for flow cytometry experiments to detect expression of the surface markers
CD44 and CD133.
2.3.3

Chemotherapy Drug Sensitivity Assay

HT-29 cells and HT-29 stem cells were plated in 96-well cell culture plates at a
concentration

of

5000

cells/well.

After

cell

adherence

was

noted,

the

chemotherapeutic drug 5-Fu (Fluorouracil) was added at different concentrations for
72 hours (each concentration was tested in triplicate) and 20 mL of MTT solution was
added. The medium was discarded after four hours and 150 µL of DMSO was added
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and mixed with an oscillating movement. An optical density (OD) of 570 nm
wavelength was used as a quick approximation of cell abundance in cell culture. And
the IC50 values (the half maximal inhibitory concentration) were calculated to
determine drug efficacy.
2.3.4

Hoechst 33342 Staining

HT-29 cells and HT-29 stem cells were first scattered and digested with
EDTA-containing trypsin, before quickly diluting and mixing with DMEM/F12
medium. After washing twice with PBS, the cells were re-suspended with PBS,
mixed and incubated at 37°C for 2-3 hours. 500µl of Hoechst 33342 was added to the
cultivated cells at a final concentration of 2 µg/mL and incubated at 37°C and for 10
min. Cells were washed 3 times with PBS followed by 400 mesh screen filtration and
analysis by flow cytometry. Heochst33342 dye excites with a krypton laser: the
wavelength of excitation used was 352 nm with an expected emission wavelength
was 400-500 nm (blue).
2.3.5

Proliferation Assessment of HT-29 Colon Cancer Stem Cells and HT-29
Colon Cancer Cells

HT-29 cells and HT-29 stem cells were scattered and digested with
EDTA-containing trypsin into single cell suspensions, and 1640 medium containing
10% serum was quickly added to stop the digestion. After washing twice with PBS,
the cells were re-suspended with PBS, mixed, and pipetted into 6-well plates. Cells
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were cultured for 96 hours, cell growth was recorded, and photographs were taken
with Zeiss inverted microscope.
2.3.6

In Vivo Tumorigenesis Assay of HT-29 Colon Cancer Stem Cells and HT-29
Colon Cancer Cells

Bilateral stem cell injections were performed in the subscapularis of BALB/c
mice, and the inguinal and axillary nodal status of HT29 stem cells and HT29 cells
were noted with respect to tumorigenesis. A total of 20 average body weight of 20g,
female BALB/c nude mice were used for each cell line. The first group was set as
negative control. The second group was treated with Xeloda as a positive control. The
third, the fourth and the fifth group were enhanced with resveratrol in the dose of
50mg, 100mg, and 200mg respectively. The BALB/c mice' physical conditions were
observed after injecting the stem cells and the experiment was ended by death or by
the presence of a tumor with a diameter over 20 mm. Autopsies were performed to
determine tumorigenesis in specific locations of the animal’s body and photographs
were taken. Tumor incidence was calculated at each location of interest. Calculations
of tumor volume and the growth rate were performed according to the following
formulas:
Tumor volume (mm3) = 1 / 2ab2 (where a = tumor diameter and b is the tumor minor
diameter)
Tumor growth rate = (measurement of tumor size at the time point – starting tumor
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size) / starting tumor size.
2.3.7

Statistical Analysis

All the experimental data were analyzed using SPSS statistical software version
13.0 (IBM, Chicago, IL). A confidence interval of 95% was used and, therefore
p-values of less than 0.05 were considered statistically significant.
2.4 Results
After serum-free cultivation, HT-29 colon cancer cells formed spindle-shaped
cells, while HT-29 colon cancer stem cells showed spherical growth(Figure 1.1).
After staining with Hoechst33342, the nuclei of HT29 colon cancer cells showed
significantly less staining compared to the HT-29 colon cancer stem cells (Figure
1.2). The positive expression rate of CD133 and CD44 in HT-29 cells was 44.6% and
0.6%, respectively (Figure 1.3A). Conversely, the expression rate of CD133 and
CD44 in cultured and purified HT-29 stem cells was 92.6% and 97.8%, respectively,
and was significantly increased (p <0.001) compared to HT-29 colon cancer cells
(Figure 1.3B). Additionally, results of the in vivo experiments showed that HT-29
stem cells grew significantly faster than the HT-29 cells. Moreover, the volume of
tumors formed by HT-29 cells was twice as large as those formed by HT-29 stem
cells (Figure 1.4; p <0.05). In contrast, the growth rate of HT-29 cells was slow
(Figure 1.4), and a continuous measurement data comparisons analysis revealed that
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the difference was statistically significant (p < 0.001). Finally, the results of a drug
sensitivity assay for the chemotherapeutic drug 5-FU showed that the IC50 of HT-29
cells was 1.394 µg/mL, compared to 13.087 µg/mL in HT-29 stem cells (Figure
1.5).

Figure 2.1: Proliferation Assessment of HT-29 Colon Cancer Stem Cells and
HT-29 Colon Cancer Cell. In vitro Proliferation Assessment showed HT-29 stem
cell’s proliferative activity dramatically increased after 48 hours. Magnification 100X
Scale bar 10 micron.
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Figure 2.2: Hoechst33342 staining for HT-29 cells (A) and HT-29 stem cells (B).
Representative images are shown of Hoechst33342 staining for HT-29 cells (A) and
HT-29 stem cells (B). Magnification was 400x for both, and scale bar = 20 µm.

Figure 2.3: Flow Cytometric Analysis of CD133 and CD44 in HT-29 cells (A) and
HT-29 stem cells (B).
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Figure 2.4: In Vivo Tumorigenesis Assay of HT-29 Colon Cancer Stem Cells and
HT-29 Colon Cancer Cells

Figure 2.5: 5-FU Drug Sensitivity Assay for HT-29 Colon Cancer Stem Cells and
HT-29 Colon Cancer Cells
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2.5 Discussion
In this study, stem cells were isolated from tumor cells by culturing them in
serum-free medium. Tumor cells cannot grow in these conditions, whereas colon
cancer stem

cells

have the

ability to

auto-synthesize (Al-Hajj,

Wicha,

Benito-Hernandez, Morrison, & Clarke, 2003; Kondo, Setoguchi, & Taga, 2004). The
results showed spherical growth of the isolated HT-29 stem cells and staining with
Hochest33342 revealed a phenomenon in which dye was excluded from the nuclear
compartments. In addition, it was observed that there is a positive expression of
CD133 and CD44, at 92.6% and 97.8% respectively, suggesting that these were
correctly identified as colon cancer stem cells. Importantly, HT-29 stem cells were
much less sensitive to 5-FU in this study than HT-29 cells: the IC50 of HT-29 cells
was 1.394 µg/mL, compared to 13.087 µg/mL in HT-29 stem cells. These findings
suggest that at conventional doses, colon cancer stem cells are resistant to
chemotherapeutic drugs. Similar results were previously reported by Reya, Morrison,
Clarke and Weissman (2001). Taken together, the results suggest that isolated HT-29
stem cells had the general characteristics of colon cancer stem cells.
Previously, it had been shown that colon cancer stem cells play an important role
in the occurrence, development, recurrence, and metastasis of colon cancer, leading to
the hypothesis that they may be an important target for cancer prevention and
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treatment (Kanwar, 2012). Unfortunately, colon cancer stem cells are insensitive to
chemotherapy drugs, such as 5-FU (Dhawan et al., 2011), and the toxicity associated
with the chemotherapeutic treatment of these cells is high (Han, Shi, Gong, Zhang, &
Sun, 2013; Vinogradov & Wei, 2012). Therefore, it is of great importance to explore
new methods to inhibit colon cancer stem cells. This study explored the use of P.
oleracea extracts, as a new method to inhibit colon cancer stem cells.
2.6 Conclusion
In conclusion, this study established that there are significant differences between
HT29 colon cancer stem cells and HT29 colon cancer cells. The HT29 colon cancer
stem cells have a significantly higher Hoechst33342 staining, significantly increased
expression of CD133 and CD44 markers, significantly faster growth and have a lower
sensitivity to chemotherapeutic drug 5-FUdrug compared to the HT29 colon cancer
cells. These characteristics can be used in clinical practice to differentiate colon
cancer stem cells from colon cancer cells for diagnostic purposes.
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3.0 Chapter 2: The Effects of P. oleracea Extracts on HT-29 Stem Cells and HT-29
Cells
3.1 Abstract
Novel cancer therapies that target cancer stem cells, which has a low insensitivity
to chemotherapeutics, so as to inhibit their proliferation or induce their apoptosis is
significant to the management of cancer development, invasion, recurrence, and
metastasis. P. oleracea extract is of potential value in inhibiting the proliferation of
cancer stem cells because studies have shown that to inhibit cancer cells. However,
no study has investigated the effect of P. oleracea extracts on the proliferation and
apoptosis of colon cancer stem cells. This study investigated the effect of ethanol
extracts of P. oleracea on the proliferation and apoptosis of HT-29 cells and HT-29
stem cells. Ethanol extracts of the medicinal plant were added to the cultured cells
and the cell proliferation and apoptosis were assessed. The study found that P.
oleracea extracts can inhibit the proliferation and increases the apoptosis of colon
cancer stem cells at the cellular level in a dose-dependent manner. These results
provide a new basis for the prevention and treatment of colon cancer at the level of
colon cancer stem cells using P. oleracea extracts. 3

3

The material contained in this chapter was already submitted to Tumor Biology.
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3.2 Introduction
Colon cancer, also known as colorectal cancer, is a significant public health
problem and has been reported to account for more than 9% of all the cases of
cancers in the world (Haggar & Boushey, 2009) and the third most common type of
cancer worldwide (Fitzmaurice et al., 2015). Epidemiological data have also shown
that colon cancer is the fourth leading cause of cancer-related mortalities worldwide
(S. Liu et al., 2015). The cancer is common in both men and women with reports
indicating that the cancer accounts for 9.4% of all cancer incidences in men and
10.1% in women (Haggar & Boushey, 2009).
Several risk factors including environmental factors such as obesity (Bardou et
al., 2013), sedentary lifestyle (Durko & Malecka-Panas, 2014; Shen et al., 2014) and
unhealthy dietary habits (Béliveau & Gingras, 2007; Myles, 2014) as well as other
health conditions Terzić, Grivennikov, Karin and Karin (2010) and genetic factors
(Jackson-Thompson et al., 2006) have been shown to increase the risk of colon cancer
in both women and men. In addition to environmental and genetic factors, colon
cancer stem cells also play a significant role in the development, recurrence and
metastasis of colon cancer (Dhawan et al., 2011; L Ricci-Vitiani et al., 2008), hence
the need to inhibit the stem cells for effective colon cancer therapy.
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Currently, colon cancer is primarily managed with chemotherapy regiments of “5
fluorouracil (5FU), oxaliplatin and/or leucovorin or 5-FU, leucovorin and irinotecan
(FOLFIRI)” (Garza-Treviño et al., 2015, p.2). The drugs display anti-cancer
properties by inducing oxidative damage of the cancer cells. However, the
chemotherapy regimen has been reported to be ineffective leading to treatment
failures in 90% of metastatic colon cancer and this has been attributed to
chemoresistance (Zhao, Butler, & Tan, 2013). The oxidative damage of the cancer
cells increases the glycolysis of the cells resulting in high levels of the antioxidant
NADPH, which can be associated with chemoresistance (Wu et al., 2008).
Colon cancer stems also displays chemoresistance by expressing HIF-1α which
decreases the pro-apoptotic signaling. The expression of HIF-1α induces the
expression of decoy receptors like DcR2 which competes for the pro-apoptotic
signaling factors such as the tumor necrosis factor-related apoptosis inducing ligand.
This reduces the signaling through the apoptosis-inducing receptors and, therefore,
attenuates apoptosis thereby allowing cells to tolerate high levels of chemotherapeutic
agents (Chen et al., 2009; Flamant et al., 2010; Sullivan & Graham, 2009; Wen et al.,
2010). Indeed, there is research evidence to show that most colon cancer stem cells
are insensitive to chemotherapy and immunotherapy, leading to the development of
resistance to chemotherapy (Dhawan et al., 2011).
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The cancer stem cells are insensitive to chemotherapy hence the need for
alternative therapy. Research has shown that immunotherapy with antibodies can be
utilised as an alternative therapy. For instance, studies have shown that colon cancer
stem cells that are insensitive to 5FU can be made sensitive by the use of
interleukin-4 blocking antibody (Todaro et al., 2007, 2008). Similarly, it has been
demonstrated that the use of anti- epiregulin, epidermal growth factor family
(anti-EREG) antibodies is an effective immunotherapy against colon cancer
metastasis (Kobayashi et al., 2012). Therefore, there is research evidence to
demonstrate the effectiveness of immunotherapy against colon cancer stem cells.
However, immunotherapy is an expensive alternative to chemotherapy due to the high
cost of producing, storing and transporting the antibodies (Lynch & Murphy, 2016).
Alternatively, nanotechnology can also be utilised to suppress colon cancer stem
cells which are resistant to chemotherapy. For instance, siRNA-mediated knockdown
of the drug efflux protein MDR1 (the protein is overexpressed in colon cancer stem
cells) has

been

described

as

a nanotechnology method

of overcoming

chemoresistance by the colon cancer stem cells (Liu et al., 2009). However,
nanotechnology is also an expensive therapy which cannot be afforded by most colon
cancer patients (Kim et al., 2016). Therefore, a more affordable and effective
alternative is necessary to overcome the chemoresistance of colon cancer stem cells
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in the treatment of colon cancers.
The use of medicinal plants has been utilised as an affordable alternative for
cancer therapy and can also be utilised to overcome the chemoresistance of colon
cancer stem cells. For instance, a study by Min, Lim, Kim, Kim, and Kim (2015)
found that the leaves of Sasa quelpaertensis can inhibit colon cancer stem cells and
influence gene expression related to stem cell development. In another study, Kumar,
Kumar, Raina, Agarwal and Agarwal (2014) found that grape seed extract can inhibit
the effect of colon cancer stem cells. P. oleracea extracts, a traditional Chinese
medicine can prevent and treat colon cancer. Extracts of the plant have been to inhibit
a number of different cancer cell types (H.-Y. Jin et al., 2012). However, at present no
study has yet determined the effect of P. oleracea extract on colon cancer stem cells.
Therefore, this study investigated the effects of P. oleracea extracts on HT-29 stem
cells and HT-29 cells.
3.3 Materials and Methods
3.3.1

P. oleracea Extract Identification and Concentration Determination

The compound was extracted according to manufacturer's protocol, which is
summarized as follows: 50 g of decocted P. oleracea were pulverized for
approximately three minutes, boiled, and refluxed for 1.5 hours with 10 times the
volume of 50% ethyl alcohol. P. oleracea was filtered by 200 mesh sieve filtrations
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and the residue was extracted twice in the manner described above. The filtrates were
combined three times to reach a final volume of 100 mL and incubated in a heated
water bath (temperature 95°C). Vacuum distillation was performed to transform the
concentrated solution into oil, which was dissolved in 50 mL of ultrapure water and
centrifuged at 12000 x g for 20 min. The supernatant was retained and the sample
solution was read at 510 nm.
3.3.2

High-performance liquid chromatography-Mass Spectrometry Analysis of P.
oleracea Extracts

High-performance liquid chromatography (HPLC) was used to identify, quantify
and purify the individual components of the compounds present in the plant extract.
The P. oleracea extract was dissolved in methanol and water prior to mass
spectrometry with a method previously described by De Vos, Schipper and Hall
(2011). The analysis was carried out using Perkin Elmer Turbo Mass
Spectrophotometer (Norwalk, CTO6859, and USA). The column used was ODS
column Hedera ODS-2 column measuring 250mm × 4.6 mm at a temperature of
25OC. The mobile phase was 0.1% (v/v) formic acid in acetic acid acetonitrile. The
flow rate was 1 ml/min. The UV detector was operated at a wavelength of 358 nm.
3.3.3

Proliferation Assessment of HT-29 cells and HT-29 Stem Cells

HT-29 colon cancer stem cells and HT-29 stem cells were seeded in 21 wells of a
64

96-well plate at a concentration of 5×103; 100 μL of medium was added to each well
that did not contain cells. The P. oleracea ethyl alcohol extract was dissolved in the
complete medium after adding DMSO (concentration of less than 0.01%). After 24 hr
and normal cell culture conditions, cells from each of the 21 wells were divided into
seven treatment groups. Each group was cultured in triplicate and P.
oleracea-containing medium was added at 200 μL to a final concentration that was
dependent on the treatment group, as follows: 0 (control group), 0.07 μg/mL, 0.14
μg/mL, 0.28 μg/mL, 0.56 μg/mL, 1.12 μg/mL, and 2.25 μg/mL (experimental group).
Cells were then placed in an incubator at 37°C and 5% CO2. After incubation for 24
or 72 hours, MTT reaction liquid was added to the wells at a ratio of 100 μL:10 μL
MTT. Following another 1 hour period in the 37°C incubator, the absorbency at 450
nm (A value) was determined with a microplate reader. The following equation was
used: inhibition rate = [1 - (A value/drug adding group - A value/blank control
group)/(A value /drug group - A value /blank control group)]×100%.
3.3.4

Flow Cytometry Assay for Apoptosis after Treatment of Cells with P.
oleracea

HT-29 cells and HT-29 stem cells were scattered and digested with
EDTA-containing trypsin into single cell suspensions. Cells were stained with trypan
blue, the number of live cells was counted, and the living cell concentration was
adjusted to 1 × 104 cells/ ml. Cells were seeded into 6-well plates at 1 × 105 cells/well.
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After conventional culturing for 24 hours, the cell medium was changed and the
complete solution with P. oleracea ethyl alcohol was added at 2.25 µg/ml. No drugs
were added to the control group: only culture medium was present. After 72 hours of
reaction, the old solution was discarded and the cells were washed once with PBS,
before adding 1 mL of a digestive solution containing EDTA and trypsin, which was
incubated for 1-2 min at 37°C. Cells were observed carefully, and at the point when
they exhibited around appearance serum-containing medium was added to stop the
digestion. Using a sucker device to blow and suck several times, the cells detached to
form a monoplast suspension, and were moved to centrifuge tubes and incubated for
1 hours at 37°C. The cells were centrifuged at 2000 rpm for 5mins at room
temperature and re-suspended with 500µl of annexin binding buffer. In the dark, 5.0
µL of Annexin V-FITC(AV) and propidium iodide (PI) dye was added and allowed to
mix for 15 min at 4°C, followed by analysis by flow cytometry. PI dye excites with
an argon ion laser: the excitation light wavelength is 488 nm with an emission
wavelength of over 630 nm (red). The subsequent analysis included blue to red
fluorescence scatterplots or topographic maps.
3.3.5

Statistical Analysis
All the experimental data were analyzed using SPSS statistical software

version 13.0 (IBM, Chicago, IL). A confidence interval of 95% was used and,
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therefore p-values of less than 0.05 were considered statistically significant.
3.4 Results
3.4.1

Compounds Present in P. oleracea Extracts, Identified by HPLC-MS

The mass spectrometry analysis of the ethanol extracts of P. oleracea showed
that the plant contains five flavonoid components; quercetin, kaempferol, myricetin,
apigenin, and luteolin (Figure 2.1). The HPLC analysis also identified non-flavonoid
components of the extract(Figure 2.2); cyclopentanecarboxylic acid, furan, 9HFluorene, benzeneacetic acid, andazaheneicosanoic acid (Table 2.1).

Figure 3.1: Flavonoid Components XIC Manager screening of Ethanol P.
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oleracea Extracts with water(A) and extract with ethanol(B).

Figure 3.2 HPLC chromatogram of P.oleracea extract with water(A) and
extract with ethanol(B) The components were identified by mass spectrometry
analysis at a mobile phase of 0.1% (v/v) formic acid in acetic acid acetonitrile. The
UV detector was operated at a wavelength of 358 nm and separation performed on an
ODS column Hedera ODS-2 column (250mm × 4.6mm) at a temperature of 25OC.
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Table 3.1
Non-flavonoid Components of Ethanol Extracts of P. oleracea
Peak
NO

Molecular
formula

Identification
Cyclopentanecarboxylic

1

C35H44O6

acid, 1-[2-[2-[2(triphenylmethoxy) ethoxy]
ethoxy]ethoxy]-, 1,1dimethylethyl ester
Furan, 4-(1,1-

2

C32H36O2

dimethylethyl)-5-[4-(9,9dimethyl-9H-fluoren-2-yl)-3methoxyphenyl]-2,3dihydro-3,3-dimethyl-

9H-Fluorene, 9-[2,4-

3

C39H40O4

cyclopentadien-1-ylbis(3,4dimethoxyphenyl)methyl]-2,
3,6,7-tetramethyl-
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Structure

Benzeneacetic acid, 3,5-

4

C35H40O6

bis(phenylmethoxy)-, (1R,
2S,5E)-1,2,6-trimethyl-7oxo-7-(2-propen-1-yloxy)-5hepten-1-yl ester, rel-

9H-Fluorene, 9-[2-[3-[1-

5

C36H36O

ethyl-1-(2-methoxyphenyl)
propyl]-1H-inden-1-yl]ethyl]
-

5,8,11,14,17,20-Hexaoxa-

6

C18H35NO9

3-azaheneicosanoic acid, 2(2-methylpropyl)-4-oxo-,
(2S)-

3.4.2

Effect of P. oleracea extracts on the Proliferation of HT-29 Cells and HT-29
Stem Cells

The results of a proliferation assay showed that HT-29 cells proliferated more
slowly than HT-29 stem cells (Figure 2.2). P. oleracea extracts exerted an inhibitory
effect on the proliferation of HT-29 cells and HT-29 stem cells after 72 hours at
concentrations ranging from 0.07 - 2.25 μg/mL, and the level of inhibition was found
to increase with dosage (Figure 2.2). Interestingly, P. oleracea extracts had a
significantly more potent effect on HT-29 colon cancer cells than on HT-29 colon
cancer stem cells, based on a repeated measurement data comparisons analysis of
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different treatment concentrations (p < 0.001). However, for both cell types, as the
concentration increased, the difference in the rate of proliferation inhibition was
reduced.

Figure 3.3: Proliferation Assay for HT-29 Cells and HT-29 Stem Cells and the
Effect of P. oleracea Extract. Stem cells were treated with varying concentrations of
P. oleracea extract, as indicated, and the effect on proliferation of both cell types was
measured after 72 hours of culture. The inhibition rate was determined by an MTT
assay, and the ratio was calculated as indicated in the methods. An increased
inhibition ratio is associated with a significantly higher inhibition rate of proliferation
(p-value < 0.001).
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3.4.3

The effect of P. oleracea Extracts on Apoptosis, as Measured by Flow
Cytometry.

Treatment with P. oleracea extract (2.25 µg/mL) resulted in a significant increase
in apoptosis in both HT-29 stem cells and HT-29 cells (Figure 2.3; p <0.05 and
p<0.025, respectively) compared to untreated controls. Taken together with the
previous section, this result suggests that P. oleracea extract can inhibit the
proliferation of cancer stem cells by inducing apoptosis.

Figure 3.4: The Effects of P. oleracea Extracts on Apoptosis of HT-29 Cells and
HT-29 Stem Cells. Cells were stained for markers of cell viability: propidium iodine
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(PI) and Annexin V (AV). Viable cells are AV and PI negative. Increased uptake of
AV is correlated with apoptosis. Double staining with AV and PI is consistent with
late apoptosis or dead cells. (A) Untreated HT-29 cells (B) HT-29 cells treated with
2.25 µg/mL P. oleracea (C) Untreated HT-29 stem cells (D) HT-29 stem cells treated
with 2.25 µg/mL P. oleracea. (E) Quantification of flow cytometry data shown in
A-D. AV positive cells were considered apoptotic (upper and lower right quadrants).
3.5 Discussion
The results of this study showed that P. oleracea extracts can inhibit the
proliferation of both colon cancer cells and colon cancer stem cells in a
dose-dependent manner. When treated with lower concentrations of P. oleracea, the
inhibition rate was higher in colon cancer cells than in colon cancer stem cells by
more than a two-fold difference. Additionally, P. oleracea extracts induced apoptosis
in both cell types. The dosage used in this study was a comparatively low dose of P.
oleracea extract. A study by Al-Sheddi et al. (2015) utilized doses of 250-1000
µg/mL to inhibit the liver cancer cell line HepG2 and lung cancer cell line A-549, the
lowest dose being 100 times higher than the highest dose in this study.
Similarly, many previous studies have found beneficial effects of P. oleracea on
cancer cells. For instance, a study by Ji et al. (2015) showed that P. oleracea extract
inhibits the proliferation, invasion, and metastasis of the liver cancer cell line
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HCCLM3. Another study by Gu et al. (2015) found that both fresh and dry P.
oleracea extract inhibit liver cancer cell proliferation and have anti-oxidant effects. In
addition, Farshori et al. (2014) reported that P. oleracea extract can inhibit the
influence of liver cancer cells. Finally, a study by Zhao et al. (2013) found that P.
oleracea extracts can inhibit cervical cancer cells. However, this is the first study to
show that P. oleracea has a similar influence on colon cancer and can inhibit colon
cancer stem cells.
3.6 Conclusion
In conclusion, the results of this study show that P. oleracea extracts can inhibit
the proliferation and increases the apoptosis of colon cancer stem cells at the cellular
level in a dose-dependent manner. These results provide a new basis for the
prevention and treatment of colon cancer at the level of colon cancer stem cells using
P. oleracea extracts.
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4.0 Chapter 3: The Effects of P. oleracea Extracts on the Expression of Notch1,
Notch2, and Beta-Catenin mRNA in HT-29 Cells and HT-29 Stem Cells
4.1 Abstract
The Notch signal transduction pathway has been shown to be important for the
development of colon cancer stem cells (H.-Y. Jin et al., 2012; Qiao & Wong, 2009).
After translation, the Notch pathway has also been shown to regulate the
Beta-Catenin mRNA in stem cells (Kwon et al., 2011). This study investigated the
effect of P. oleracea extracts on the expression of Notch1, Notch2, and Beta-Catenin
mRNA in HT-29 cells and HT-29 stem cells. It was found that P. oleracea extracts
significantly down-regulate the expression of Notch1 and β-catenin in both HT-29
cells and HT-29 stem cells. However, the treatment of HT-29 cells and HT-29 stem
cells with P. oleracea extract caused a slight increase in expression of Notch2,
although this difference was not statistically significant. This suggests that alterations
in the Notch signal transduction pathway underlie the inhibitory effects of P. oleracea
on proliferation, as well as the increase in apoptosis, of colon cancer stem cells. 4

4

The material contained in this chapter was already submitted to Tumor Biology.
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4.2 Introduction
The main properties of colon cancer stem cells (which plays a significant role in
the development, recurrence, and metastasis of colon cancers) include self-renewal
potential, ability to differentiate into diverse cell populations and ability to balance
and modulate the processes of self-renewal and differentiation (Garza-Treviño et al.,
2015). Self-renewal refers to the ability of the colon cancer stem cells synthesize new
cells with the same ability to proliferate, expand and differentiate as the parental cells
thereby maintaining a pool of the stem cell (Garza-Treviño et al., 2015). The
mechanisms utilised for the self-renewal of the colon cancer stem cells, such as the
Wnt/β-catenin and Notch pathways, makes use of proto-oncogenes. In addition, the
self-renewal pathway of colon cancer stem cells is regulated by the sonic hedgehog
(Hh) signaling pathway, a pathway commonly reported in multiple myeloma (Varnat
et al., 2009). Research has shown that the self-renewal of colon cancer stem cells is
promoted by the Wnt pathway and the prevention of the β-catenin-dependent
transcription (Ong et al., 2014).
Additionally, the Notch receptors pathway has also been reported to promote the
self-renewal of colon cancer stem cells (Ong et al., 2014). In the Notch pathway, the
DLL4 genes stimulate the Notch receptors on adjacent cells and in combination with
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the effects of β-catenin promotes the self-renewal of the cancer stem cells by
directing an immature transcription profile (Garza-Treviño et al., 2015). However, the
self-renewal pathways are inhibited by BMP4 genes which bind BMP receptors
leading to interference with the Wnt pathway and thus promote cell differentiation.
The process of differentiation has also been reported to be inhibited by hepatocyte
growth factor (HGF) leading to the maintenance of the cells in a stem-cell state (Ong
et al., 2014).
Cancer stem cells also have the ability into differentiate into diverse cell
populations (Garza-Treviño et al., 2015). That is, the stem cells have the ability to
differentiate into a heterogeneous progeny of cells that can undergo progressive
diversification and specialization following self-renewal. The cells of this
differentiation are specialized to carry out certain unique physiological functions
(Dalerba, Cho, et al., 2007). However, histopathological studies of colon cancers have
indicated that the cells are relatively undifferentiated containing higher proportions of
colon cancer stem cells than more differentiated cancer cells (Ashley et al., 2013;
Merlos-Suárez et al., 2011). The undifferentiated colon cancer cells have worse
clinical prognosis compared to differentiated cancer cells (Merlos-Suárez et al.,
2011).
Homeostatic control where the cells have the ability to balance and modulate the
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processes of self-renewal and differentiation is also a key property of cancer stem
cells (Garza-Treviño et al., 2015). Through research, it has been established that
differentiated intestinal epithelial cells reside in the intestinal crypts as repeats of
stem cells containing leucine and B lymphoma Mo-MLV insertion region 1 homolog
(Bmi-1) or G protein-coupled receptor 5 (Lgr5) (Tian et al., 2011). The Bmi-1 AND
Lgr5 are used to maintain the capacity of tissues to regenerate (Tian et al., 2011). The
intestinal cells that express Lgr5 undergo active proliferation and very sensitive to
stimulatory effects of Wnt and Dkk1-mediated Wnt inhibition (Tian et al., 2011). On
the other hand, intestinal cells that express Bmi-1 are less sensitive to environmental
stressors and are, therefore, not affected by the Wnt modulation. The
Bmi-1-expressing intestinal cells are normally quiescent, only giving rise to cell
progeny under certain conditions (Yan et al., 2012). The Wnt proteins and the Notch
pathway has been reported to play a significant role in maintaining cancer stem cells
hemostasis by providing signals required for the maintenance of the phenotype of
colon cancer stem cells in the tumour mass (Garza-Treviño et al., 2015).
Based on these three properties of colon cancer stem cells, it can be deduced that
the dysregulation of the Notch pathway and Beta-Catenin mRNA plays a role in the
development of cancer. Therefore, the ability of P. oleracea extracts to inhibit the
proliferation but promote the apoptosis of colon cancer stem cells, in case of any,
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may suggest that the extracts dysregulate the Notch pathway and Beta-Catenin
mRNA. However, there is no study that has investigated the effect of P. oleracea
extracts on the expression of Notch1, Notch2, and Beta-Catenin mRNA in HT-29
cells and HT-29 stem cells. Therefore, this study investigated the effect of P.
oleracea extracts on the expression of Notch1, Notch2, and Beta-Catenin mRNA in
HT-29 cells and HT-29 stem cells.
4.3 Materials and Methods
4.3.1

Real-time Fluorescence Quantitative PCR (FQ-PCR) Assay for the
Expression of Notch1, Notch2, and β-catenin mRNA

HT29 cells were cultured in McCoy's 5A medium with 10% FBS, while HT29
stem cells were cultured in RPMI-1640 medium with 10% FBS. Both cell strains
were seeded at a concentration of 5 × 105 cells/mL in complete medium containing 10
cm dishes, with two dishes for each strain. After 24 hours under normal conditions, a
complete medium that contained the following concentrations of P. oleracea extract
was added: 0 μg/mL (control group) or 2.25 μg/mL (experiment group). After 72
hours in an incubator at 37° and 5% C02, the cells were washed twice with pre-cooled
PBS. Total RNA was isolated with Trizol kit. RNA was reverse-transcribed to cDNA
(Real Time PCR) using the primers shown in Table 3.1. Ribosome 18S (18S rRNA)
was used as an internal reference.
Table 4.1
Primers used for the Quantitative RT-PCR Assay
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Gene

Primer

Primer sequence

Length

Notch1

Notch1 (+)

CCGCAGCACTATTGAGAACA

213 bp

Notch1 (-)

ATCCATGTGTAGCCGTAGCC

Notch2 (+)

TAATACGACTCACTATGAGA

Notch2 (-)

ATTTAGGTGACACTATCTGT

β-catenin (+)

AAGTTCTTGGCTATTACGCA

β-catenin (-)

ACAGCACCTTCAGCACTATG

18s rRNA (+)

TTTGTTGGTTTTCGGAACTGA

18s rRNA (–)

CGTTTATGGTCGGAACTACGA

Notch2

β-catenin

18s rRNA

4.3.2

229 bp

203 bp

198 bp

Western Blot Assays for the Expression of ß-catenin, Notch1, and Notch2
Proteins

HT-29 cells and HT-29 stem cells were treated with 2.25 μg/mL of P. oleracea
extract, a cell scraper was used to lift cells in the primary culture solution, total
protein was extracted, and a Western blot assay was prepared, according to the
manufacturer. The total grey value in the resulting Western blots was measured with
Band Scan Analysis software, which allowed for a quantitative comparative analysis.
Measurements were normalized to β-actin.
4.3.3

Statistical Analysis

All the experimental data were analyzed using SPSS statistical software version
13.0 (IBM, Chicago, IL). A confidence interval of 95% was used and, therefore
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p-values of less than 0.05 were considered statistically significant.
4.4 Results
4.4.1

Expression of Notch1, Notch2, And Β-Catenin mRNA in HT-29 Colon
Cancer Cells And HT-29 Colon Cancer Stem Cells with and Without
Treatment with P. Oleracea Extracts.

At baseline, the expression of Notch1, Notch2, and β-catenin mRNA was lower
in HT-29 colon cancer cell lines than in HT-29 colon cancer stem cells. While the
differences in the expression of Notch1 and β-catenin were statistically significant,
the differences in Notch2 were not significant (Table 3.2). After treatment with P.
oleracea extract (2.25 μg/mL), the expression of Notch1 and β-catenin in both HT-29
cells and HT-29 stem cells were significantly down-regulated. Conversely, treatment
with P. oleracea extract caused a slight increase in expression of Notch2, although
this difference was not statistically significant (Table 3.3).

Table 4.2
Expression of Notch1, Notch2, and β-catenin mRNA in HT-29 cells and HT-29
stem cells
HT-29 cells
HT-29 stem
(mean±SD)
cells(mean±SD)
p-value
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β-catenin

1.16 ± 0.17

2.34 ± 0.28

0.003

Notch1

1.01 ± 0.01

1.66 ± 0.03

<0.001

Notch2

1.11 ± 0.11

1.16 ± 0.10

0.584

Table 4.3
Expression of Notch1, Notch2, and β-catenin mRNA in HT-29 cells and
HT-29 stem cells after treatment with P. oleracea (mean±SD)
β-catenin
Notch1
Notch2
HT-29 cells
1.16 ± 0.17
1.01 ± 0.01
1.11 ± 0.11
+ P. oleracea
0.003 ± 0.0004
0.004 ± 0.001
1.93 ± 0.30
p-value
0.000
0.000
0.32
HT-29 stem cells
2.34 ± 0.28
1.66 ± 0.03
1.16 ± 0.10
+ P. oleracea
0.003 ± 0.001
0.003 ± 0.0003
1.37 ± 0.067
p-value
<0.001
<0.001
0.053

4.4.2

Results of Western Blot Analyses for β-catenin, Notch1, and Notch2

Treatment with P. oleracea extracts decreased the expression of Notch1, Notch2,
and β-catenin protein in HT-29 cells and HT-29 stem cells (Table 3.4, Figure 3.1).
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Table 4.4
Relative expression of Notch1, Notch2, and β-catenin proteins in HT-29 cells
and HT-29 stem cells after treatment with P. oleracea compared to β-actin
β-catenin

Notch1

Notch2

HT-29 stem cells

1.64

1.26

0.69

HT-29 stem cells + P. oleracea

0.16

0.41

0.03

p-value

0.027

0.032

0.052

HT-29 cells

0.70

0.45

0.17

HT-29 cells + P. oleracea

0.55

0.32

0.05

p-value

0.002

0.011

0.355

Figure 4.1: Representative Western blots for the expression of proteins in the
Notch signal transduction pathway after treatment with P. oleracea. Lane 1:
HT-29 stem cells + P. oleracea; Lane 2: HT-29 cells + P. oleracea; Lane 3: HT-29
stem cells; Lane 4: HT-29 cells.
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4.5 Discussion
The Notch signal transduction pathway is an important regulator gene for the
development of colon cancer stem cells (H.-Y. Jin et al., 2012; Qiao & Wong, 2009).
Preliminary results have shown that tea polyphenol can inhibit and regulate the
genetic effects of the Notch signal transduction pathway (H. Jin, Tan, Liu, & Ding,
2010). The target genes of the Notch signal transduction pathway are closely related
to colon cancer stem cells and include Notch1, Notch2, and β-catenin. In this study, it
was found that the expression of Notch1 and β-catenin mRNA was significantly
higher in colon cancer stem cells than in colon cancer cell lines. This suggests that
Notch1 and β-catenin gene expression decreases when colon cancer stem cells mature.
However, the reason for this is unclear and requires further study. Importantly, this
study established that treatment with P. oleracea extracts inhibited the expression of
Notch1 and β-catenin mRNA by close to 10-fold. Taken together, it is possible that
alterations in the Notch signal transduction pathway underlie the inhibitory effects of
P. oleracea on proliferation, as well as the increase in apoptosis, of colon cancer stem
cells. At present, there are only a limited number of studies on P. oleracea extract;
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therefore, next study will continue to explore the possible mechanisms underlying
these suppressive effects on colon cancer stem cells.
4.6 Conclusion
In conclusion, this study established that P. oleracea extracts significantly inhibit
the expression of Notch1 and β-catenin mRNA by close to 10-fold, suggesting that
alterations in the Notch signal transduction pathway underlie the inhibitory effects of
P. oleracea on proliferation, as well as the increase in apoptosis, of colon cancer stem
cells.
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5.0 Summary and Future Perspective
Given the importance of preventing and treating colon cancer at the level of the
cell, a number of difference avenues have been explored for inhibiting colon cancer
stem cells. Aside from immunological therapy, chemotherapy, and the other standard
treatments, some investigators have reported on the merits of using natural drugs or
foods to prevent and treat this disease. For example, a study by Min, Lim, Kim, Kim,
and Kim (2015) found that the leaves of Sasa quelpaertensis can inhibit colon cancer
stem cells and influence gene expression related to stem cell development. In another
study, Kumar, Kumar, Raina, Agarwal and Agarwal (2014) found that grape seed
extract can inhibit the effect of colon cancer stem cells. Similarly, in this study,
alcohol was used to extract the flavone content of P. oleracea, and this extract was
found to inhibit colon cancer and colon cancer stem cells. These findings suggest that
P. oleracea extract could represent a potential option in the prevention and treatment
of colon cancer, as well as for adjuvant therapy.
The results of this study demonstrated that P. oleracea extracts can inhibit colon
cancer stem cells at the cellular level in a dose-dependent manner. This result
provides a new basis for the prevention and treatment of colon cancer at the level of
colon cancer stem cells using P. oleracea extracts. This study also established that P.
oleracea extracts significantly inhibit the expression of Notch1 and β-catenin mRNA
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by close to 10-fold, suggesting that alterations in the Notch signal transduction
pathway underlie the inhibitory effects of P. oleracea on proliferation, as well as the
increase in apoptosis, of colon cancer stem cells. However, further studies should be
conducted to explore the possible mechanisms underlying these suppressive effects
on colon cancer stem cells considering the limited number of studies on P. oleracea
extracts in this area currently.
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